Catheter

Brainomix and Nanoflex Robotics to Collaborate on an AI-Assisted Robotic System for Remote Stroke Intervention

Retrieved on: 
Thursday, October 12, 2023
Physician, Stroke, Intelligence, Innovation Agency (Azerbaijan), United Kingdom, Innovation, Robotics, Innovate UK, CHF, Artificial intelligence, Catheter, Patient, Medical device, Pharmaceutical industry

The grant, administered by Innovate UK, the United Kingdom's innovation agency, and Innosuisse, Switzerland's Innovation Agency, awarded Brainomix and Nanoflex Robotics £400,000 and CHF 400,000 respectively.

Key Points: 
  • The grant, administered by Innovate UK, the United Kingdom's innovation agency, and Innosuisse, Switzerland's Innovation Agency, awarded Brainomix and Nanoflex Robotics £400,000 and CHF 400,000 respectively.
  • Starting in 2024, Nanoflex Robotics and Brainomix will collaborate to create an artificial intelligence-assisted magnetic navigation system for robotic surgical tools.
  • The project aims to leverage the power of artificial intelligence to enhance Nanoflex Robotics' cutting-edge magnetic robotic navigation system to be the first system worldwide to enable remote thrombectomy, thus transforming stroke treatment options and helping improve outcomes for patients."
  • Nanoflex Robotics' first product will be a mobile robotics system that utilizes ultra-flexible guidewires to allow for direct steering control of the tip.

Brainomix and Nanoflex Robotics to Collaborate on an AI-Assisted Robotic System for Remote Stroke Intervention

Retrieved on: 
Thursday, October 12, 2023
Physician, Stroke, Intelligence, Innovation Agency (Azerbaijan), United Kingdom, Innovation, Robotics, Innovate UK, CHF, Artificial intelligence, Catheter, Patient, Medical device, Pharmaceutical industry

The grant, administered by Innovate UK, the United Kingdom's innovation agency, and Innosuisse, Switzerland's Innovation Agency, awarded Brainomix and Nanoflex Robotics £400,000 and CHF 400,000 respectively.

Key Points: 
  • The grant, administered by Innovate UK, the United Kingdom's innovation agency, and Innosuisse, Switzerland's Innovation Agency, awarded Brainomix and Nanoflex Robotics £400,000 and CHF 400,000 respectively.
  • Starting in 2024, Nanoflex Robotics and Brainomix will collaborate to create an artificial intelligence-assisted magnetic navigation system for robotic surgical tools.
  • The project aims to leverage the power of artificial intelligence to enhance Nanoflex Robotics' cutting-edge magnetic robotic navigation system to be the first system worldwide to enable remote thrombectomy, thus transforming stroke treatment options and helping improve outcomes for patients."
  • Nanoflex Robotics' first product will be a mobile robotics system that utilizes ultra-flexible guidewires to allow for direct steering control of the tip.

UltraNav System Enables Safer and More Cost-Effective Transseptal Procedures by Aligning Catheter and Ultrasound

Retrieved on: 
Wednesday, October 11, 2023
Hospital, Congenital heart defect, Physician, PFO, ICE, PST, Cardiology, Heart, Safety, TEE, Learning curve, Catheter, RF, FDA, Orientation, ASD, Anesthesia, Needle, DIB, TCT, Patient, Medical device, Medical imaging

SCOTTSDALE, Ariz., Oct. 11, 2023 /PRNewswire/ -- Franklin Mountain Medical announced today that the Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for use in atrial transseptal procedures and delivery of catheters, has now been successfully used in 15 human cases, at major cardiology hospitals in Arizona and Minnesota.

Key Points: 
  • The significant rise in structural transseptal heart procedures mandates the need for a safer, more accurate approach.
  • UltraNav improves the safety and accuracy of transseptal procedures by enabling better visualization of the catheter, needle, and needle tip.
  • "There's been a significant rise in structural transseptal heart procedures, which mandates the need for a safer, more accurate approach," said Dr. Nabil Dib, founder of Dib UltraNav Medical and inventor of the UltraNav Transseptal Catheter System.
  • The single-use, dual-lumen, non-steerable Dib UltraNav System intravascular catheter and handle received FDA 510(k) clearance in March 2022.

HR Pharmaceuticals, Inc. significantly expands the TruCath® portfolio with two new offerings of ready-to-use intermittent catheters delivering optimal protection, comfort, and convenience

Retrieved on: 
Tuesday, October 10, 2023
Investment, Risk, HRP, Catheter, DME, Medical device

TruCath Swift Pre-Lubricated Intermittent Catheters and TruCath Oasis Ready-to-Use Hydrophilic Catheters are ready to use out of the package – no lubricant application or coating activation is required – saving time and reducing mess.

Key Points: 
  • TruCath Swift Pre-Lubricated Intermittent Catheters and TruCath Oasis Ready-to-Use Hydrophilic Catheters are ready to use out of the package – no lubricant application or coating activation is required – saving time and reducing mess.
  • Both products feature the TruProtect™ grip, providing controlled, no-touch handling to help reduce the risk of cross-contamination.
  • "The launch of TruCath Swift and TruCath Oasis is a defining moment for HRP and further solidifies the TruCath product line in the market.
  • To learn more about the extensive range of TruCath products, including TruCath Swift and TruCath Oasis Intermittent Catheters, visit http://trucath.com .

InventHelp Inventors Develop Pet Urine Sample Collection Device (NPL-463)

Retrieved on: 
Monday, October 9, 2023
Multimedia, Urine, Sanitation, DEPT, Invention, Suite, Catheter, Sale, Trapping

Our design would be easy to position and it offers an alternative to using traditional specimen collection methods, such as dishes, manual collection procedures or catheters."

Key Points: 
  • Our design would be easy to position and it offers an alternative to using traditional specimen collection methods, such as dishes, manual collection procedures or catheters."
  • The invention provides a convenient tool for collecting a urine sample from a dog or cat for veterinarian clinical urinalysis.
  • The invention features a portable and practical design that is easy to use so it is ideal for pet owners, veterinarian offices, animal shelters, etc.
  • 21-NPL-463, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval

Retrieved on: 
Wednesday, October 4, 2023
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, Elixir, Percutaneous coronary intervention, Medicine, Plaque, AC 25.1309-1, BRS, CAD, Pharmaceuticals and Medical Devices Agency, Catheter, TLF, PCI, Resolute, Motion, Catheterization laboratory, Standard of care, Patient, Physician, PMDA, Division, Randomized controlled trial, Stent, Coronary artery disease, Pharmaceutical industry

Elixir Medical , a developer of disruptive cardiovascular technologies, announced submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) for the approval of the DynamX® Coronary Bioadaptor System for the treatment of coronary artery disease (CAD).

Key Points: 
  • Elixir Medical , a developer of disruptive cardiovascular technologies, announced submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) for the approval of the DynamX® Coronary Bioadaptor System for the treatment of coronary artery disease (CAD).
  • DynamX coronary bioadaptor was developed to overcome the limitations of drug-eluting stents (DES) and bioresorbable scaffolds (BRS).
  • “Our submission for approval in Japan is an exciting milestone for the company and industry.
  • The DynamX coronary bioadaptor represents a culmination of major design and manufacturing breakthroughs and three clinical trials consistently demonstrating differentiated functional performance compared to the standard of care,” said Motasim Sirhan, CEO of Elixir Medical.

Freudenberg Medical Celebrates Opening of Expanded Manufacturing Facility, Creating 100 New Jobs in Galway, Ireland

Retrieved on: 
Monday, October 2, 2023
Other Manufacturing, Medical Devices, Surgery, Medical Supplies, Chemicals, Plastics, Manufacturing, Biotechnology, Pharmaceutical, Health, Oncology, Medicine, Freudenberg Group, Multimedia, Research, Catheter, History, Engineering, Growth, Medical device

Freudenberg Medical , a leading global design and manufacturing partner for minimally invasive medical devices, has announced the creation of 100 new jobs, as it marks the official opening of its newly expanded facility in Galway, Ireland.

Key Points: 
  • Freudenberg Medical , a leading global design and manufacturing partner for minimally invasive medical devices, has announced the creation of 100 new jobs, as it marks the official opening of its newly expanded facility in Galway, Ireland.
  • View the full release here: https://www.businesswire.com/news/home/20231001933940/en/
    Freudenberg Medical's expanded hypotube manufacturing facility in Galway, Ireland (Photo: Business Wire)
    The company, which is part of the Freudenberg Group , celebrated the official opening of its expanded facility today at an event attended by Dr. Mohsen Sohi, CEO of the Freudenberg Group.
  • Commenting on today’s announcement, CEO of Freudenberg Medical, Dr. Mark Ostwald, said the opening of the expanded facility was a significant milestone for the company’s Irish operations.
  • Its Irish facilities were originally established as joint venture partnerships with the former Cambus Medical and VistaMed operations which have now transitioned into Freudenberg Medical.

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

Retrieved on: 
Friday, September 22, 2023
Center of excellence, ISO, Catheter, SALT, Engineering, Growth, 3D printing

Biomerics announces the completion of a 100,000-square-foot expansion of its operations in Brooklyn Park, Minnesota, bringing the facility to a total size of 170,000 square feet

Key Points: 
  • Biomerics announces the completion of a 100,000-square-foot expansion of its operations in Brooklyn Park, Minnesota, bringing the facility to a total size of 170,000 square feet
    Biomerics' main facility in Brooklyn Park specializes in designing, developing and manufacturing complex, highly specialized catheters, steerable devices and delivery systems for the interventional device market.
  • Tom Winegar, President of Biomerics Brooklyn Park, says, "This expansion consolidates all Biomerics' Minnesota operations under one roof.
  • "This expansion reflects our 30-year pursuit of innovation and manufacturing excellence," says Travis Sessions, Chief Executive Officer of Biomerics.
  • The expansion will continue to fuel our growth with best-in-class speed-to-market capabilities."

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

Retrieved on: 
Friday, September 22, 2023
Center of excellence, ISO, Catheter, SALT, Engineering, Growth, 3D printing

Biomerics' main facility in Brooklyn Park specializes in designing, developing and manufacturing complex, highly specialized catheters, steerable devices and delivery systems for the interventional device market.

Key Points: 
  • Biomerics' main facility in Brooklyn Park specializes in designing, developing and manufacturing complex, highly specialized catheters, steerable devices and delivery systems for the interventional device market.
  • Tom Winegar, President of Biomerics Brooklyn Park, says, "This expansion consolidates all Biomerics' Minnesota operations under one roof.
  • "This expansion reflects our 30-year pursuit of innovation and manufacturing excellence," says Travis Sessions, Chief Executive Officer of Biomerics.
  • The expansion will continue to fuel our growth with best-in-class speed-to-market capabilities."

M&L Healthcare's First MedTech Investment Receives FDA Approval Following Successful US Trials

Retrieved on: 
Monday, September 18, 2023
Chin Na, Amputation, The New England Journal of Medicine, M&L, CE marking, Type 2 diabetes, Catheter, Johannes Hoffmann (vascular surgeon), Vein, Statistics, COVID-19, Clinical trial, Foot, Quality of life, St Luke's Hospital, Singapore, Leg, Artery, Changi General Hospital, Elective surgery, PMA, Transcatheter arterial chemoembolization, Patient, Investment, MD, Series, Engineering, Mortality, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medtech, Food, Wound healing, Pharmaceutical industry, Medical device, Valvulotome, EU, CLTI

The approval comes after successful outcomes in the PROMISE II Pivotal trial in the United States, recently published in the New England Journal of Medicine.

Key Points: 
  • The approval comes after successful outcomes in the PROMISE II Pivotal trial in the United States, recently published in the New England Journal of Medicine.
  • It is the first and only FDA-approved device for TADV and provides no-option CLTI patients with access to a minimally invasive treatment.
  • Type 2 diabetes is a major cause of CLTI, a condition that affects millions of people globally.
  • The United States alone witnesses approximately 150,000 ischemic amputations each year, resulting in healthcare costs of over US$95 billion.